PE75399A1 - Granulos entericos de fluoxetina - Google Patents

Granulos entericos de fluoxetina

Info

Publication number
PE75399A1
PE75399A1 PE1998000430A PE00043098A PE75399A1 PE 75399 A1 PE75399 A1 PE 75399A1 PE 1998000430 A PE1998000430 A PE 1998000430A PE 00043098 A PE00043098 A PE 00043098A PE 75399 A1 PE75399 A1 PE 75399A1
Authority
PE
Peru
Prior art keywords
fluoxetine
granules
optional
layer
hydroxypropylmethyllchell
Prior art date
Application number
PE1998000430A
Other languages
English (en)
Inventor
Neil Robert Anderson
Roger Garrick Harrison
Daniel Frederick Lynch
Peter Lloyd Oren
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE75399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE75399A1 publication Critical patent/PE75399A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

CARACTERIZADO PORQUE COMPRENDE a)NUCLEO DE CLORHIDRATO DE FLUOXETINA DE 20mg A 100 mg, b)CAPA DE SEPARACION OPCIONAL TAL COMO SACAROSA, c)CAPA ENTERICA QUE COMPRENDE SUCCINATO ACETATO DE HIDROXIPROPILMETILCELULOSA (HPMCAS), SE NEUTRALIZAN EL 0%-15% DE LOS GRUPOS SUCCINILO CON AMONIACO; d)CAPA DE TERMINACION OPCIONAL. EL TAMANO MEDIO DE PARTICULA DE FLUOXETINA ES APROXIMADAMENTE 50 um O MENOS. LOS GRANULOS ESTAN CONTENIDOS EN CAPSULAS DE GELATINA. TAMBIEN SE REFIERE A UN PROCEDIMEINTO PARA LA PREPARACION. LA FORMULACION COMPRENDE ADEMAS PINDOLOL PUEDE SER UTIL PARA EL TRATAMIENTO DE DEPRESION, TRASTORNO OBSESIVO COMPULSIVO, BULIMIA, DOLOR, TRASTORNOS DE PERSONALIDAD
PE1998000430A 1997-05-29 1998-05-28 Granulos entericos de fluoxetina PE75399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (1)

Publication Number Publication Date
PE75399A1 true PE75399A1 (es) 1999-08-17

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000430A PE75399A1 (es) 1997-05-29 1998-05-28 Granulos entericos de fluoxetina

Country Status (46)

Country Link
US (3) US5910319A (es)
JP (1) JP3210288B2 (es)
KR (1) KR100549473B1 (es)
CN (2) CN1161109C (es)
AR (1) AR011728A1 (es)
AT (1) AT408068B (es)
AU (1) AU726690B2 (es)
BE (1) BE1011925A3 (es)
BR (1) BR9801989A (es)
CA (1) CA2234826C (es)
CH (1) CH693018A5 (es)
CO (1) CO4940407A1 (es)
CZ (1) CZ290582B6 (es)
DE (1) DE19823940B4 (es)
DK (1) DK176776B1 (es)
ES (1) ES2161574B1 (es)
FI (1) FI119971B (es)
FR (1) FR2763846B1 (es)
GB (1) GB2325623B (es)
GR (1) GR980100188A (es)
HK (1) HK1034902A1 (es)
HU (1) HUP9800882A3 (es)
ID (1) ID20343A (es)
IL (1) IL124073A (es)
IT (1) ITMI980908A1 (es)
LT (1) LT4477B (es)
LU (1) LU90245B1 (es)
LV (1) LV12176B (es)
MY (1) MY118139A (es)
NL (1) NL1009259C2 (es)
NO (1) NO317743B1 (es)
NZ (1) NZ330192A (es)
PE (1) PE75399A1 (es)
PL (1) PL192293B1 (es)
PT (1) PT102152B (es)
RO (1) RO120043B1 (es)
RS (1) RS49827B (es)
RU (1) RU2164405C2 (es)
SE (1) SE522914C2 (es)
SG (1) SG72805A1 (es)
SI (1) SI9800128B (es)
SV (1) SV1998000052A (es)
TR (1) TR199800937A2 (es)
TW (1) TWI239838B (es)
UA (1) UA48193C2 (es)
ZA (1) ZA983173B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
DK1178780T3 (da) * 1999-05-20 2007-11-12 Elan Corp Plc Multipartikelformige formuleringer til kontrolleret frigivelse af selektiv serotoningenoptagelseshæmmer
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
EP1889614A3 (en) 1999-09-03 2010-09-22 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004058228A1 (en) * 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
JP4901474B2 (ja) 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
WO2005105045A1 (ja) * 2004-04-30 2005-11-10 Astellas Pharma Inc. 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
AU2006274565B2 (en) * 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
CA2629800A1 (en) * 2005-11-23 2007-05-31 Thomas G. Gant Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
CN101426478A (zh) * 2006-02-24 2009-05-06 特瓦制药工业有限公司 氟伐他汀钠药物组合物
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
EP2016066A4 (en) * 2006-05-10 2010-11-24 Reddys Lab Ltd Dr PROCESS FOR PREPARING DULOXETINE
BRPI0711606A2 (pt) * 2006-05-22 2012-02-14 Teva Pharma formulações de hidrocloreto de duloxetina de liberação retardada
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20090175935A1 (en) * 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
SI2317852T1 (sl) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja
WO2010026993A1 (ja) * 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
US20120207825A1 (en) * 2009-09-17 2012-08-16 Sunilendu Bhushan Roy Pharmaceutical compositions for reducing alcohol-induced dose dumping
EP2540318B1 (en) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
ES2728850T3 (es) * 2012-05-02 2019-10-29 Capsugel Belgium Nv Dispersiones acuosas de acetato acetato succinato de hidroxipropilmetilcelulosa (HPMCAS)
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
ES2706994T3 (es) 2012-09-03 2019-04-02 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015179073A1 (en) * 2014-05-20 2015-11-26 Dow Global Technologies Llc Capsule shells comprising an esterified cellulose ether
WO2015179072A1 (en) 2014-05-20 2015-11-26 Dow Global Technologies Llc Dispersion comprising a partially neutralized esterified cellulose ether
US10564114B2 (en) * 2014-06-07 2020-02-18 Structure-Ase Incorporated Method for the detection and/or diagnosis of eating disorders and malnutrition using X-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3609578A4 (en) 2017-04-13 2021-03-10 Chase Therapeutics Corporation PHARMACEUTICAL COMBINATION AND ITS USE FOR THE TREATMENT OF SYNUCLEINOPATHIES
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
WO1992013452A1 (en) * 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
AU2154892A (en) * 1991-05-07 1992-12-21 Dynagen, Inc. A controlled, sustained release delivery system for treating drug dependency
ATE173159T1 (de) * 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
ATE198547T1 (de) * 1993-11-03 2001-01-15 Isomed Inc Mizelleförmige feinteilige pharmazeutische zusammensetzungen
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
AT408068B (de) 2001-08-27
BE1011925A3 (fr) 2000-03-07
TR199800937A3 (tr) 1999-10-21
GB2325623B (en) 1999-04-14
AR011728A1 (es) 2000-08-30
ITMI980908A1 (it) 1999-10-28
SE522914C2 (sv) 2004-03-16
FR2763846A1 (fr) 1998-12-04
FI119971B (fi) 2009-05-29
TWI239838B (en) 2005-09-21
CO4940407A1 (es) 2000-07-24
RO120043B1 (ro) 2005-08-30
USRE39030E1 (en) 2006-03-21
PT102152A (pt) 1998-12-31
CZ114398A3 (cs) 1998-12-16
RS49827B (sr) 2008-08-07
DE19823940B4 (de) 2010-04-29
KR100549473B1 (ko) 2006-03-23
LU90245A1 (es) 1998-11-30
JPH10330253A (ja) 1998-12-15
PT102152B (pt) 2000-09-29
NO982197D0 (no) 1998-05-14
SE9801336D0 (sv) 1998-04-17
AU726690B2 (en) 2000-11-16
SV1998000052A (es) 1999-03-16
JP3210288B2 (ja) 2001-09-17
LT98058A (en) 1998-10-26
LT4477B (lt) 1999-03-25
CN1161109C (zh) 2004-08-11
YU16598A (en) 1999-11-22
IL124073A (en) 2002-02-10
NO982197L (no) 1998-11-30
KR19980086622A (ko) 1998-12-05
US5910319A (en) 1999-06-08
ES2161574A1 (es) 2001-12-01
GR980100188A (el) 1999-01-29
LU90245B1 (fr) 2002-07-31
HUP9800882A3 (en) 2000-07-28
SG72805A1 (en) 2000-05-23
CA2234826A1 (en) 1998-11-29
LV12176A (lv) 1998-12-20
SI9800128B (sl) 2000-04-30
NZ330192A (en) 1999-08-30
ID20343A (id) 1998-12-03
CH693018A5 (de) 2003-01-31
FR2763846B1 (fr) 2001-05-18
CN1212834C (zh) 2005-08-03
DK176776B1 (da) 2009-08-10
FI980846A0 (fi) 1998-04-16
GB9807939D0 (en) 1998-06-10
HK1034902A1 (en) 2001-11-09
TR199800937A2 (xx) 1999-10-21
NL1009259C2 (nl) 1998-12-01
DE19823940A1 (de) 1998-12-03
ZA983173B (en) 1999-10-15
PL192293B1 (pl) 2006-09-29
PL326134A1 (en) 1998-12-07
ATA93198A (de) 2001-01-15
SI9800128A (sl) 1999-02-28
CA2234826C (en) 2000-12-19
SE9801336L (sv) 1998-11-30
GB2325623A (en) 1998-12-02
LV12176B (en) 1999-03-20
CZ290582B6 (cs) 2002-08-14
CN1200924A (zh) 1998-12-09
RU2164405C2 (ru) 2001-03-27
US5985322A (en) 1999-11-16
HUP9800882A2 (hu) 2000-03-28
NO317743B1 (no) 2004-12-13
ES2161574B1 (es) 2002-06-16
MY118139A (en) 2004-09-30
BR9801989A (pt) 2000-02-08
FI980846A (fi) 1998-11-30
AU6904898A (en) 1998-12-03
CN1285189A (zh) 2001-02-28
IE980284A1 (en) 2000-07-12
UA48193C2 (uk) 2002-08-15
HU9800882D0 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
PE75399A1 (es) Granulos entericos de fluoxetina
PT1077688E (pt) Sistema terapeutico transdermico contendo pergolide
WO2000069421A3 (de) Transdermales therapeutisches system (tts) tolterodin enthaltend
DZ3326A1 (fr) Composés nouveaux modulateurs de chimiokine ccr5, et compositions pharmaceutiques les contenant.
ATE429210T1 (de) Orale flüssige zusammensetzungen
ATE223712T1 (de) Pharmazeutische zusammensetzung von l-dopa ethyl ester
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
FR2772763B1 (fr) Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
TW490306B (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
WO2021091125A1 (ko) 충격 분산 기능을 강화한 치과 치료용 임플란트의 어뷰트먼트
RU99124179A (ru) Комбинация анальгетиков
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
PT1063983E (pt) Sistema terapeutico transdermico (tts) contendo oxibutinina
HUP9904073A2 (hu) Bizmutot és nemszteroid gyulladásgátló hatóanyagot tartalmazó készítmények gasztrointesztinális rendellenességek kezelésére
DE69928375D1 (de) Analgetikum aus schlangengift
NO992999L (no) Farmasöytisk blanding for oral administrering
RU97120507A (ru) Фармацевтические композиции для лечения хронического алкоголизма
KR970073593A (ko) 진세노사이드 Rg_5를 함유하는 항암제 조성물
DE69602788D1 (de) Monocarbonate, ihre Anwendung und Verfahren zur Herstellung von Monocarbonaten enthaltenden Kompositionen
AR017170A1 (es) Composicion oftalmologica
RU96122910A (ru) Лекарственное средство
RU93037432A (ru) Лекарственное средство для лечения рассеянного склероза
TH29868A (th) วิธีการและองค์ประกอบของสารสำหรับทำให้สีของผิวหนังจางลง
RU96120655A (ru) Композиция для профилактики и лечения гриппа и орви

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed